📍 1 Triton Square, London NW1 3DX
Join us as part of London Life Sciences Week to explore how research, startups and innovation can connect Japan with global ecosystems. Meet pioneering Japanese university-linked startups and hear perspectives from Japan, the UK and Boston on turning research into global impact.
Powered by NINEJP
Join us to open an evening of international collaboration connecting Japan, the UK and Boston. This session introduces NINEJP, a national network bringing together nine university startup support platforms across Japan to support the creation and growth of globally competitive university-linked startups.
Through opening remarks and an introduction to NINEJP’s activities, participants will learn about the delegation’s goals: showcasing research-driven innovation from Japan, exploring international partnerships and laying the foundations for a lasting innovation community. The session sets the scene for the startup showcase and panel discussion that follow, inviting participants to explore how research, talent, investment and markets can connect across borders.
This event includes showcases from the following Startups:
PURMX Therapeutics: A Hiroshima University spin-out drug discovery copmany which is developing revolutionary new drugs that kills cancer cells in a state of infinite growth.
RAINBOW Inc: A Hokkaido University spin-off biotechnology company developing regenerative therapies for neurological diseases.
xFOREST Therapeutics: An RNA-targeted small-molecule drug discovery company leveraging its proprietary high-throughput screening (HTS) platform to quantitatively assess target selectivity and address traditionally undruggable diseases.
EditForce: A biotechnology company developing gene therapies based on its proprietary RNA-targeting PPR protein platform.
Toregem BioPharma: A biotechnology company pioneering antibody-based tooth regeneration therapies for congenital tooth agenesis and missing teeth
Meet three university-linked startups from Japan and discover the technologies, ideas and ambitions driving their international growth. Each team will deliver an approximately five-minute pitch, introducing the challenge it addresses, what makes its technology distinctive and why it is looking to engage with the UK and wider international markets.
Beyond company introductions, the speakers will highlight the partners and opportunities they are seeking, helping participants identify potential connections in investment, joint research, proof-of-concept projects and business collaboration. The showcase offers a starting point for conversations that can continue during the evening’s networking.
The companies showcasing include:
PURMX Therapeutics: A Hiroshima University spin-out drug discovery copmany which is developing revolutionary new drugs that kills cancer cells in a state of infinite growth.
RAINBOW Inc: A Hokkaido University spin-off biotechnology company developing regenerative therapies for neurological diseases.
xFOREST Therapeutics: An RNA-targeted small-molecule drug discovery company leveraging its proprietary high-throughput screening (HTS) platform to quantitatively assess target selectivity and address traditionally undruggable diseases.
EditForce: A biotechnology company developing gene therapies based on its proprietary RNA-targeting PPR protein platform.
Toregem BioPharma: A biotechnology company pioneering antibody-based tooth regeneration therapies for congenital tooth agenesis and missing teeth
How can Japan and the UK accelerate deep-tech innovation together, and how can connections with Boston create further opportunities for collaboration?
Bringing together perspectives from Japan, the UK and Boston, this panel explores how research excellence can translate into global impact. The discussion goes beyond the creation of new ventures to consider research commercialisation, startup growth, investment, market access, joint research and corporate partnerships.
Panellists will examine how the ecosystems’ strengths in research, technology, capital, talent and markets can complement one another. They will explore both the opportunities for Japanese startups and researchers to engage internationally and the value that UK and Boston partners can find through deeper collaboration with Japan. The conversation will conclude with practical steps towards joint projects, investment and lasting cross-border relationships.
Feel free to join us from 6-9pm for the London Life Sciences Week Wrap Event, hosted at One Triton Square with Venture Café. Hear insights from London's leading life sciences organisations, meet showcasing startups and connect with over 300 delegates as we close the week. Register for the event here
Megumi Ikeda is a General Partner at Ode Growth Partners, a European tech growth fund investing in founders building mission-critical software for critical industries. Previously, she was Senior Managing Director at Hearst Ventures, where she led European investments for the U.S. media conglomerate. Prior to that, Megumi headed the European arm of a GE Capital-sponsored equity fund. Earlier in her career, she worked in New York on corporate M&A and distribution for NBCUniversal. Megumi began her career in Tokyo as a reporter for Dow Jones and later was at Wired in the early years of the Internet. She holds a BA from Columbia College, Columbia University, and an MBA from UCLA Anderson.
Mike Jackson is the Head of Venture Café UK. As an ex-entrepreneur and a Tech Ecosystem builder for the last decade, he first launched WebStart Bristol, a regional accelerator programme, before delivering growth programmes across the UK for Tech Nation, before replicating this model globally for Startup Genome. In his role at Head of Venture Café UK, he is responsible for delivering on their activation partnership with ARIA - curating weekly innovation gatherings and connecting startups, investors, researchers and corporates to drive collaboration across the UK's deeptech and science ecosystem.
Physician, Neurosurgeon. Lecturer at Hokkaido University Graduate School of Medicine. He is known for many extensive experiences in stem cell therapy for brain diseases, having won numerous awards and recognized as a leading researcher in stem cell research both domestically and internationally.
Founding scientist of the company.
Koji Murota serves as Deputy Executive Director for Social Collaboration and Innovation Initiatives at Kyoto University. With over 25 years of experience in venture capital, technology commercialization, and industry-academia collaboration, he has played a key role in advancing university-driven innovation in Japan. He previously served as President and CEO of Kyoto University Innovation Capital and Director-General of the university’s Office of Society-Academia Collaboration for Innovation. He also represents the Keihanshin Startup Academia Coalition (KSAC), fostering entrepreneurship and startup ecosystem development across the Kansai region.
Michal is currently focused on building BioMed X Venture Labs, a “Build-to-Solve” biotech startup co-creation engine that partners with pharma, disease-focused foundations, and investors to identify critical challenges and build startups designed to solve them. Previously, she was Senior Vice President at J&J, leading the Johnson & Johnson Innovation East North America team to identify, negotiate and execute partnerships and investments to feed the company's global pharma and med tech product pipelines. Earlier, she held senior leadership roles at Harvard, biotech and tech companies, helping advance technologies, forge industry alliances, and launch startups. An active Boston innovation leader, she has served on numerous corporate and nonprofit boards. Among those, she is currently an advisor to Jefferson Life Sciences venture fund. Michal holds a PhD from Weizmann Institute, and an MBA from INSEAD. She is a devoted mentor and supporter of early career innovators and founders.
Dr. Hidetoshi Tahara graduated from Tokyo University of Pharmacy and Life Sciences in 1989 and received his Ph.D. in 1994. After serving as an assistant professor and associate professor at the Faculty of Pharmaceutical Sciences, Hiroshima University, he was appointed professor in 2006. Since 2021, he has also served as Vice President (Startup Ecosystem), leading the university's industry-academia collaboration and startup initiatives. He established the "Hiroshima LOVE it Consortium" and has promoted global industry-academia collaboration through digital transformation (DX). In this role, he is also overseeing the launch of the Hiroshima University Vaccine and Pharmaceutical Manufacturing Facility, a GMP-compliant facility scheduled to begin operation in September 2026.
Building on his basic research on telomeres and microRNAs, he founded MiRTeL Co., Ltd. in 2012 and PURMX Therapeutics Co., Ltd. in 2021 to develop microRNA-based therapeutics. PURMX's lead candidate, MIRX002, has completed two investigator-initiated clinical trials (MIRX002-01 and MIRX002-02) in patients with malignant pleural mesothelioma, demonstrating a favorable safety and tolerability profile. A further clinical trial evaluating intratumoral administration of MIRX002 in head and neck cancer is ongoing and nearing completion. He received the Special Award at EY Entrepreneur Of The Year 2022 Japan and the Special Award at Academic Startups 2022, and PURMX Therapeutics was selected as a winner of Johnson & Johnson's Japan Smart Healthy Aging QuickFire Challenge 2025.
Beth White is Deputy Director for Trade, Investment and Exports at the Office for Life Sciences (OLS). She joined OLS from the Department for Business and Trade in June 2025 and is a career civil servant with experience in business relationship management, sponsorship of partner organisations and regulatory policy. Beth leads OLS's international trade, investment, and export activity, including support for inward investment, international company account management, market access, and promotion of UK life sciences globally.